Oligometastatic Prostate Cancer

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Varian Medical Systems
1 program
1
177Lu-PSMAPhase 21 trial
Active Trials
NCT05560659RecruitingEst. May 2027
Arcus Biosciences
1 program
1
QuemliclustatPhase 2Small Molecule1 trial
Active Trials
NCT05915442RecruitingEst. Dec 2028

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
Varian Medical Systems177Lu-PSMA
Arcus BiosciencesQuemliclustat

Clinical Trials (2)

Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy

Start: Dec 2023Est. completion: May 2027
Phase 2Recruiting

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Start: Jul 2023Est. completion: Dec 2028
Phase 2Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials
2 companies competing in this space